Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South

Clinical Infectious Diseases(2025)10.1093/cid/ciaf425Source: DataRank Database

Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South is a research paper published in Clinical Infectious Diseases (2025). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 7.02)OA: hybridTopics (54)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Amalia Aldredge ORCID,Larisa Niles-Carnes ORCID,Eudiah Ochieng,Priyasha Pareek,Vickie Robinson

Live enrichment

PubMed:40747944 OpenAlex:https://openalex.org/W4412823811

National Institutes of Health

Grant: R01MH123396

National Institutes of Health

Grant: T32AI157855

National Institutes of Health

Grant: K23HL152903

National Institutes of Health

Grant: K23AG084415

Emory Center for AIDS Research

Grant: P30AI050409

FWCI

7.02

Citation Percentile

1.0%

Citation Trend

2025

2026

hybridLicense: other-oa

journalhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaf425/63907164/ciaf425.pdf

publisherhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaf425/63907164/ciaf425.pdf

publisherhttps://academic.oup.com/cid/article-pdf/82/4/564/63907164/ciaf425.pdf

journalhttps://doi.org/10.1093/cid/ciaf425

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40747944

Fields of Study

HIV/AIDS Research and InterventionsHIV Research and TreatmentHIV/AIDS drug development and treatmentHumansHIV InfectionsFemaleMaleViremiaRetrospective StudiesAdultMiddle AgedHIV-1Anti-HIV AgentsRilpivirinePyridonesViral LoadAntibodies, Monoclonal, HumanizedWhiteAcetamidesAntibodies, MonoclonalIndazolesDiketopiperazines

MeSH Terms

RilpivirineAcetamidesWhiteAdultAntibodies, MonoclonalFemaleHumansIndazolesMaleMiddle AgedPyridonesRetrospective StudiesViremiaHIV-1HIV InfectionsAnti-HIV AgentsViral LoadDiketopiperazinesAntibodies, Monoclonal, Humanized

Keywords

RilpivirineViremiaMedicineViral loadHuman immunodeficiency virus (HIV)Antiretroviral therapyInternal medicineVirologyIbalizumabLenacapavirSouthern Hiv/aids EpidemicPersons With Hiv-1 ViremiaLong-acting Injectable Cabotegravir/rilpivirine

Sustainable Development Goals

SDG 0: No poverty